Real-world data confirms limited efficacy of dual anti-PD-1 and CTLA-4 immune checkpoint blockade in acral lentiginous melanoma

Br J Dermatol. 2024 Nov 15:ljae445. doi: 10.1093/bjd/ljae445. Online ahead of print.

Authors

David X Zheng^{1

2}, Russell W Jenkins^{1

2}

Affiliations

¹ Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
² Broad Institute of MIT and Harvard, Cambridge, MA, USA.

PMID: 39545493
DOI: 10.1093/bjd/ljae445

No abstract available

Publication types

Editorial
Comment